Watson nets Barr exec as CEO
Executive Summary
Barr President and Chief Operating Officer Paul Bisaro will succeed longtime Watson CEO and founder Allen Chao, effective Sept. 4. Bisaro has worked for Barr since 1992, and became president and COO in 2006. Among his more recent accomplishments is helping guide the acquisition of Pliva, which closed in October 2006 (1"The Pink Sheet" Oct. 30, 2006, In Brief). Barr CEO Bruce Downey will now take over Bisaro's responsibilities on an interim basis, according to Barr, which maintains there is no "urgency" in naming a replacement. Barr also will need to re-evaluate its succession plan, as Bisaro was widely viewed as the choice to take over when Downey retires...
You may also be interested in...
Watson Will Pursue “Balanced” Generic Portfolio, CEO Bisaro Says
Watson Pharmaceuticals will aim for a "balanced" generic drug portfolio by moving beyond "commodity" products to include more of those that are especially difficult to formulate or manufacture, new President and CEO Paul Bisaro said during the firm's third quarter earnings call Nov. 6
Barr/Pliva acquisition final
Barr's acquisition of Croatian generics firm Pliva closes Oct. 24. Barr was able to own or control in excess of 95% of Pliva's voting share capital by the Oct. 11 deadline, the threshold necessary for a takeover under Croatian law. FTC approval of the $2.5 bil. deal was contingent upon Barr divesting the generic antidepressant trazodone and its generic blood pressure medication triamterene/hydrochlorothiazide to Apotex, as well as divesting either its own or Pliva's nimodipine soft gel capsules and Pliva's branded organ preservation solution Custodial. Barr cites Pliva's European infrastructure and biogeneric capabilities as the main reasons for the merger (1"The Pink Sheet" July 3, 2006, p. 16)....
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”